Altamira Therapeutics Ltd. (NASDAQ:CYTO) Short Interest Up 238.9% in November

Altamira Therapeutics Ltd. (NASDAQ:CYTO) saw a large increase in short interest in the month of November. As of November 15th, there was short interest totalling 105,400 shares, an increase of 238.9% from the October 31st total of 31,100 shares. Based on an average trading volume of 74,600 shares, the days-to-cover ratio is currently 1.4 days. Approximately 2.8% of the shares of the company are sold short.

Altamira Therapeutics Trading Down 4.5 %

Shares of NASDAQ:CYTO traded down $0.02 during mid-day trading on Thursday, reaching $0.40. 56,414 shares of the company traded hands, compared to its average volume of 724,693. The company’s 50 day moving average price is $0.56 and its 200-day moving average price is $0.96. Altamira Therapeutics has a 52 week low of $0.40 and a 52 week high of $17.20.

Altamira Therapeutics Company Profile

Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens.